Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PSA-1 and SELECT-PsA-2 trials assessed according to modified PsARC

Схожие документы

• Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC
  по: Coates, LC, и др.
  Опубликовано: (2021)
• Assessment of the many faces of PsA: single and composite measures in PsA clinical trials
  по: McGagh, D, и др.
  Опубликовано: (2020)
• Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study
  по: Iain B. McInnes, и др.
  Опубликовано: (2022-10-01)
• Anti-LL37 Antibodies Are Present in Psoriatic Arthritis (PsA) Patients: New Biomarkers in PsA
  по: Loredana Frasca, и др.
  Опубликовано: (2018-09-01)
• Treat-to-target in PsA: methods and necessity
  по: Dures, E, и др.
  Опубликовано: (2020)